Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a rare but severely disabling variant within the spectrum of trigeminal autonomic cephalalgia lacking evidence-based treatment.Read More →
CGRP has an important pathophysiological role in cluster headache. Chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with CGRP antibodies.Read More →
Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology.Read More →
Targeting the calcitonin gene-related peptide (CGRP) pathway to treat these headaches may be the first focused therapeutic option to date, with the potential for promising efficacy.Read More →
Any discussion of cluster headache eventually includes treating cluster headache with psychedelics as an alternative to medical treatment.Read More →
Chronic cluster headache (CH) is a rare, highly disabling primary headache condition. As NMDA receptors are possibly overactive in CH, NMDA receptor antagonists, such as ketamine, could be of interest in patients with intractable CH.Read More →
